Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2024-06-28 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于确定公司回购股份用途的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from a company regarding the determination of the purpose of repurchased shares. It details the board meeting resolutions about the use of repurchased shares, specifically for converting company bonds into stock. The document does not contain financial statements or detailed financial data but is a formal disclosure about share repurchase usage and related board decisions. It is not a full financial report, earnings release, or management discussion. It fits the category of a Transaction in Own Shares (POS) as it relates to the company's repurchase and use of its own shares.
2024-06-28 Chinese
《公司章程》修正案
Governance Information Classification · 95% confidence The document is a formal announcement from the board of directors of 健帆生物科技集团股份有限公司 regarding the amendment of the company's Articles of Association (公司章程) due to the cancellation of repurchased shares and the consequent reduction in registered capital and total share capital. It details specific changes in registered capital and share structure. The document is dated June 28, 2024, and states that the matter requires shareholder approval. The content focuses on corporate governance and capital structure changes, specifically the amendment of the Articles of Association, which is a governance document. There is no financial statement or detailed financial report included, nor is it a simple announcement of a report publication. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices, including amendments to the Articles of Association.
2024-06-28 Chinese
公司章程（2024年6月）
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of 健帆生物科技集团股份有限公司 dated June 2024. It contains detailed company governance rules, shareholder rights, board structure, share issuance, share transfer, and shareholder meeting procedures. It is a comprehensive governance document outlining the internal rules and organizational structure of the company rather than a financial report or announcement. There is no indication of financial statements, audit opinions, earnings data, or meeting results. The content matches the definition of Governance Information (CGR), which covers the company's internal rules, board structure, and governance practices.
2024-06-28 Chinese
关于增加闲置自有资金现金管理额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the increase of the cash management limit for idle funds. It details the investment amount, purpose, risk analysis, and approval procedures, including board and supervisory committee meetings. The document does not contain financial statements or detailed financial performance data. It is a regulatory announcement about capital management activities, specifically about increasing the cash management limit, which relates to financing and capital structure updates. The document length is about 2905 characters, which is relatively short and focused on a specific capital management decision rather than a full financial report or earnings release. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-06-28 Chinese
2021年健帆生物科技集团股份有限公司创业板向不特定对象发行可转换公司债券2024年跟踪评级报告
Audit Report / Information Classification · 95% confidence The document is a detailed credit rating report for a convertible bond issued by 健帆生物科技集团股份有限公司, dated 2024. It includes extensive financial data, credit rating opinions, industry analysis, company background, bond details, and future outlook. The content is focused on credit rating assessment rather than a general annual or quarterly financial report. It is not an earnings release, call transcript, or management report. The document is lengthy (15,000 characters) and contains substantive financial and operational analysis related to credit rating. This matches the characteristics of an Audit Report / Information (AR) type, which includes standalone audit or credit rating reports and related financial analysis, but is not a full annual report (10-K) or interim report (IR). Therefore, the appropriate classification is AR with high confidence. Q1 2024
2024-06-28 Chinese
关于健帆转债2024年付息的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the interest payment on its convertible bonds for the year 2024. It details the bond code, interest rates, payment dates, tax information, and other bond-related specifics. There is no financial statement, management discussion, or detailed financial data. The document is primarily an update on a capital market instrument's interest payment schedule and related procedural information. This fits the category of Capital/Financing Update (CAP), as it relates to bond interest payment and financing activities rather than a full financial report or regulatory filing.
2024-06-17 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.